www.degruyter.com Open in urlscan Pro
2600:9000:236e:2e00:0:435c:8840:93a1  Public Scan

Form analysis
3 forms found in the DOM

/search?query=

<form class="form-inline" action="/search?query=">
  <div class="input-group flex-grow-1">
    <input class="mainNavbarSearchInput form-control input-header rounded-start py-1" type="search" aria-label="Suche" name="query" placeholder="degruyter.com durchsuchen" value="">
    <div class="input-group-append">
      <button class="btn btn-primary rounded-end analyticsButton" aria-label="Suche" type="submit"><span class="fa fas fa-search ga_main_search_button"></span></button>
    </div>
  </div>
</form>

/search?query=

<form class="form-inline" action="/search?query=">
  <div class="input-group flex-grow-1">
    <input class="mainNavbarSearchInput form-control input-header rounded-start py-1" type="search" aria-label="Suche" name="query" placeholder="degruyter.com durchsuchen" value="">
    <div class="input-group-append">
      <button class="btn btn-primary rounded-end analyticsButton" aria-label="Suche" type="submit"><span class="fa fas fa-search ga_main_search_button"></span></button>
    </div>
  </div>
</form>

/search/series/oncologie?query=

<form class="pt-2 font-family-standard" action="/search/series/oncologie?query=">
  <div class="input-group">
    <input class="form-control rounded-start placeholderSmallText font-size-14 py-1" type="text" name="query" aria-label="Zeitschrift durchsuchen" placeholder="Zeitschrift durchsuchen">
    <div class="input-group-append">
      <button class="btn btn-primary rounded-end analyticsButton" aria-label="Zeitschrift durchsuchen" type="submit">
        <span class="fa fas fa-search ga_parent_search_button"></span>
      </button>
    </div>
  </div>
  <label><input hidden="hidden" name="documentVisibility" value="all"></label>
</form>

Text Content

Zum Hauptinhalt springen
Sollten Sie Zugang über eine Institution haben? Hier sehen Sie wie das
funktioniert ...
€ EUR - Euro
£ GBP - Pound
$ USD - Dollar
DE
English Deutsch
0
Einloggen
Einloggen Noch kein Konto? Registrieren Sie ein neues Konto Passwort
zurücksetzen
Fachgebiete
Abschnitt überspringen
Publikationen nach Fachgebiet finden

 * Allgemein
 * Altertumswissenschaften
 * Architektur und Design
 * Asien- und Pazifikwissenschaften
 * Bibliotheks- und Informationswissenschaft, Buchwissenschaft
 * Biologie
 * Chemie
 * Geowissenschaften
 * Geschichte
 * Industrielle Chemie

 * Informatik
 * Islam- und Nahostwissenschaft
 * Jüdische Studien
 * Kulturwissenschaften
 * Kunst
 * Linguistik und Semiotik
 * Literaturwissenschaft
 * Materialwissenschaft
 * Mathematik
 * Medizin

 * Musik
 * Pharmazie
 * Philosophie
 * Physik
 * Rechtswissenschaften
 * Sozialwissenschaften
 * Sport und Freizeit
 * Technik
 * Theologie und Religion
 * Wirtschaftswissenschaften

Services
Abschnitt überspringen
Für Zeitschriftenautoren

 * Veröffentlichen Sie Ihren Artikel
 * Der Status als Autor/-in
 * Sichtbarkeit für Ihren Artikel

Für Buch-Autoren

 * Warum mit De Gruyter publizieren
 * Wie mit De Gruyter publizieren
 * Unsere Buchreihen
 * Unsere Fachgebiete

Für Bibliothekare

 * Produktinformationen
 * Tools & Ressourcen
 * FAQs
 * Kontakt

Rechte & Berechtigungen

 * Repository Policy
 * Free access policy

Publikationen
Abschnitt überspringen
Open Access

 * Open-Access-Bücher
 * Open-Access-Artikel
 * Open-Access-Vereinbarungen

Publikationsarten

 * Bücher
 * Zeitschriften
 * Datenbanken
 * Datenbankportale

Themen die wir veröffentlichen

 * Allgemein
 * Altertumswissenschaften
 * Architektur und Design
 * Asien- und Pazifikwissenschaften
 * Bibliotheks- und Informationswissenschaft, Buchwissenschaft
 * Biologie
 * Chemie
 * Geowissenschaften
 * Geschichte
 * Industrielle Chemie

 * Informatik
 * Islam- und Nahostwissenschaft
 * Jüdische Studien
 * Kulturwissenschaften
 * Kunst
 * Linguistik und Semiotik
 * Literaturwissenschaft
 * Materialwissenschaft
 * Mathematik
 * Medizin

 * Musik
 * Pharmazie
 * Philosophie
 * Physik
 * Rechtswissenschaften
 * Sozialwissenschaften
 * Sport und Freizeit
 * Technik
 * Theologie und Religion
 * Wirtschaftswissenschaften

Über uns
Abschnitt überspringen
Kontakt

 * Für Autoren
 * Kundenservice
 * Human Resources
 * Presse
 * Vertrieb
 * Journal Management

 * Partnerverlage
 * Open Access
 * Mediadaten
 * Rezensionsexemplare
 * Prüfexemplare
 * Kontakt Rechte, Lizenzen & Datenschutz

Karriere

 * Ihre Einstiegsmöglichkeiten
 * Stellenausschreibungen
 * Arbeiten bei De Gruyter

Über De Gruyter

 * Vision & mission
 * Imprints
 * Geschichte
 * Stiftung
 * De Gruyter Ebound
 * Unsere Standorte
 * Unsere Verantwortung

Partnerverlage

 * Partnerverlage
 * Presse
 * FAQs

0

Einloggen Noch kein Konto? Registrieren Sie ein neues Konto Passwort
zurücksetzen
FACHGEBIETE
Publikationen nach Fachgebiet finden
 * Allgemein
 * Altertumswissenschaften
 * Architektur und Design
 * Asien- und Pazifikwissenschaften
 * Bibliotheks- und Informationswissenschaft, Buchwissenschaft
 * Biologie
 * Chemie
 * Geowissenschaften
 * Geschichte
 * Industrielle Chemie
 * Informatik
 * Islam- und Nahostwissenschaft
 * Jüdische Studien
 * Kulturwissenschaften
 * Kunst
 * Linguistik und Semiotik
 * Literaturwissenschaft
 * Materialwissenschaft
 * Mathematik
 * Medizin
 * Musik
 * Pharmazie
 * Philosophie
 * Physik
 * Rechtswissenschaften
 * Sozialwissenschaften
 * Sport und Freizeit
 * Technik
 * Theologie und Religion
 * Wirtschaftswissenschaften

SERVICES
Für Zeitschriftenautoren
 * Veröffentlichen Sie Ihren Artikel
 * Der Status als Autor/-in
 * Sichtbarkeit für Ihren Artikel

Für Buch-Autoren
 * Warum mit De Gruyter publizieren
 * Wie mit De Gruyter publizieren
 * Unsere Buchreihen
 * Unsere Fachgebiete

Für Bibliothekare
 * Produktinformationen
 * Tools & Ressourcen
 * FAQs
 * Kontakt

Rechte & Berechtigungen
 * Repository Policy
 * Free access policy

PUBLIKATIONEN
Open Access
 * Open-Access-Bücher
 * Open-Access-Artikel
 * Open-Access-Vereinbarungen

Publikationsarten
 * Bücher
 * Zeitschriften
 * Datenbanken
 * Datenbankportale

Themen die wir veröffentlichen
 * Allgemein
 * Altertumswissenschaften
 * Architektur und Design
 * Asien- und Pazifikwissenschaften
 * Bibliotheks- und Informationswissenschaft, Buchwissenschaft
 * Biologie
 * Chemie
 * Geowissenschaften
 * Geschichte
 * Industrielle Chemie

 * Informatik
 * Islam- und Nahostwissenschaft
 * Jüdische Studien
 * Kulturwissenschaften
 * Kunst
 * Linguistik und Semiotik
 * Literaturwissenschaft
 * Materialwissenschaft
 * Mathematik
 * Medizin

 * Musik
 * Pharmazie
 * Philosophie
 * Physik
 * Rechtswissenschaften
 * Sozialwissenschaften
 * Sport und Freizeit
 * Technik
 * Theologie und Religion
 * Wirtschaftswissenschaften

ÜBER UNS
Kontakt
 * Für Autoren
 * Kundenservice
 * Human Resources
 * Presse
 * Vertrieb
 * Journal Management

Karriere
 * Ihre Einstiegsmöglichkeiten
 * Stellenausschreibungen
 * Arbeiten bei De Gruyter

Über De Gruyter
 * Vision & mission
 * Imprints
 * Geschichte
 * Stiftung
 * De Gruyter Ebound
 * Unsere Standorte
 * Unsere Verantwortung

Partnerverlage
 * Partnerverlage

 * Presse

 * FAQs

Sprache ändern
English Deutsch
Währung ändern
€ EUR £ GBP $ USD



Ihr Kauf ist abgeschlossen. Ihre Dokumente können jetzt angezeigt werden.


Open Access Veröffentlicht seit 1. Januar 2023


ONCOLOGIE

ISSN: 1765-2839
Editors-in-Chief: Jean Philippe Metges, Daniel Serin
Manuskript einreichen
 * Übersicht
   .
 * Neuestes Heft
 * Ausgaben
 * Metriken
 * Einreichen
 * Editorial




ÜBERSICHT


ÜBER DIESE ZEITSCHRIFT

Oncologie is aimed to the publication of high quality original research
articles, review papers, case report, etc. with an active interest in vivo or
vitro study of cancer biology. Study relating to the pathology, diagnosis, and
advanced treatment of all types of cancers, as well as research from any of the
disciplines related to this field of interest.

The journal is owned by Tech Science Press. La Société Française de Chirurgie
Oncologique (SFCO), France, l’Association Francophone pour les Soins
Oncologiques de Support (AFSOS), France, la Fédération Française des Oncologues
Médicaux (FFOM), France, and the Malaysian Association for Cancer Research
(MACR), Malaysia are affiliated with the journal Oncologie.

Oncologie is an open access journal. It publishes English-language articles
only. The publication frequency is bimonthly.

Aims & Scope

Oncologie, an international peer-reviewed journal with a group of the global
experts who are leaders in oncology in the editorial board, aims to publish
high-quality original research articles, review papers, case reports, etc. with
an active interest in vivo or in vitro study of cancer biology. Oncologie
focuses studies relating pathology, diagnosis, and advanced treatment of cancer
and research from all disciplines related to this field of interest. More
specifically, we are targeting the entire fields of cancer biology, including
but not limited to the discovery of any new factors related to cancer
initiation, progression, and systemic treatment. Other critical biological
insights are considerable for sure.

Research Topics may include Cytology, Pathology, Genetics, Gynecology,
Hematology, Immunology and Immunotherapy, Chemotherapy, Radiotherapy, Palliative
Support, Pediatric　Oncology, Solid Tumors, Modern Statistics, Meta-analysis, and
Clinical Trial Design, Surgery, Nursing, Psycho-Oncology

Oncologie is targeted at medical and health workers engaged in cancer
prevention, treatment and research, teachers and students from medical colleges
and universities, and personnel in other related disciplines.








GESCHICHTE

Former publication of Oncologie
(2004-2017): https://link.springer.com/journal/10269/volumes-and-issues
(2018-2019): https://onco.revuesonline.com/component/issues
(2019-2022): https://www.techscience.com/journal/oncologie






ZUSATZMATERIAL

 * License to Publish ONCOLOGIE
 * ONCOLOGIE_Instructions on Ethical and Legal Declarations
 * ONCOLOGIE_Template for Ethical and Legal Declarations
 * Oncologie_Instructions for Authors


FACHGEBIETE

 * Allgemeinmedizin, Innere Medizin
 * Frauenheilkunde und Geburtshilfe
 * Gynäkologische Onkologie
 * Hämatologie, Onkologie
 * Kinder- und Jugendmedizin
 * Kinderhämatolgie und -Onkologie
 * Klinische Medizin
 * Klinische Medizin, andere
 * Medizin


EXTERNE LINKS

 * Online submission of manuscripts


NEUESTES HEFT


BAND 25 HEFT 1

Januar 2023
Es konnten keine Quellenangaben für dieses Dokument abgerufen werden

Quellenangabe für das Dokument wird abgerufen...
Öffentlich zugänglich 16. März 2023

FRONTMATTER

Seiten: i-ii
Zitieren PDF downloaden



REVIEW ARTICLE

Es konnten keine Quellenangaben für dieses Dokument abgerufen werden

Quellenangabe für das Dokument wird abgerufen...
Open Access 14. Februar 2023

DIFFERENTIAL EXPRESSION AND FUNCTIONS OF MIRNAS IN BLADDER CANCER

Hao Huang, Xiaowu Pi, Chenqi Xin, Chen Gong, Feng Guo, Yang Wang, Ying Xiong
Seiten: 1-15
Mehr Zitieren PDF downloaden


ABSTRACT

Bladder cancer (BC), a urologic disease, commonly occurs globally and is very
invasive. Patients with invasive BC have low 5-year survival rate. Hence,
the mechanisms underlying BC development and progression should be elucidated.
MicroRNAs (miRNAs), as common noncoding RNAs, are receiving increasing attention
because of their biological functions. The irregular expression patterns of
miRNAs are linked to BC occurrence; therefore, determining the functions of
miRNAs in abnormally expressed BC tissues might enable to elucidate the
pathogenetic mechanism of BC and offer new markers for the prognosis, diagnosis,
and therapy of BC. Here, we consolidate the primary roles of miRNAs with
atypical expression in BC development as well as their association with BC
pathological grades and chemotherapy resistance development in patients with BC.



RESEARCH ARTICLES

Es konnten keine Quellenangaben für dieses Dokument abgerufen werden

Quellenangabe für das Dokument wird abgerufen...
Open Access 20. Februar 2023

PAN-CANCER ANALYSIS, PROVIDING A RELIABLE BASIS FOR IDO2 AS A PROGNOSTIC
BIOMARKER AND TARGET FOR IMMUNOTHERAPY

Bangqian Mo, Xiashuang Zhao, Yongfeng Wang, Xianglai Jiang, Deming Liu, Hui Cai
Seiten: 17-35
Mehr Zitieren PDF downloaden


ABSTRACT

Objectives Indoleamine 2,3-dioxygenase 2 (IDO2) is a homologous protein of the
classical immune negative regulator Indoleamine 2,3-dioxygenase 1 (IDO1) that is
indispensable in the metabolism of tryptophan and is closely related to the
pathogenesis and progression of tumors. Nevertheless, the mechanism of IDO2 in
malignant tumors is not fully understood warranting further research. Methods
Data related to IDO2 in pan-cancer was obtained from The Cancer Genome Atlas
(TCGA) database. Differences in IDO2 expression between pan-cancerous and
corresponding normal tissues were analyzed, and survival rates were analyzed
using Kaplan–Meier. The correlation between IDO2 expression and
tumor-infiltrating immune cells (TIICs), tumor mutational load (TMB),
microsatellite instability (MSI), mismatch repair (MMR), immune checkpoints
(ICP) and DNA methyltransferase (DNMT) was investigated by Spearman correlation
analysis. Functional enrichment analysis of IDO2 was performed to explore its
biological and molecular roles in tumors. Results Our comprehensive pan-cancer
analysis showed that IDO2 expression was significantly altered in most
malignancies and correlated with poor prognosis. The expression of IDO2 was
strongly associated with the progression of several tumors and excessive
infiltration of immune cells in the tumor microenvironment (TME). The expression
of IDO2 significantly correlated with TMB, MSI, MMR and ICP in different tumors.
More importantly, functional enrichment analysis showed that IDO2 acts primarily
through the regulation of antitumor immunological processes. RT-PCR validated
IDO2 expression in multiple cancer cell lines, consistent with the bioinformatic
analysis results. Conclusions IDO2 is closely related to tumor genesis and
immunity, and can be used as an adjunct for the diagnosis and prognosis
assessment of many tumors.

Es konnten keine Quellenangaben für dieses Dokument abgerufen werden

Quellenangabe für das Dokument wird abgerufen...
Open Access 27. Januar 2023

KNOCKDOWN OF PYRUVATE KINASE M2 SUPPRESSES BLADDER CANCER PROGRESSION

Guang-Cheng Luo, Ran Xu, Xi Zhang, Lin Xu, Xiao-Kun Zhao, Xin-Jun Wang
Seiten: 37-50
Mehr Zitieren PDF downloaden


ABSTRACT

Objectives Bladder cancer (BCa) is one of the most frequently diagnosed cancers
of the urinary tract and has a high mortality. The M2 splice isoform of pyruvate
kinase (PKM2) is a key regulator of the Warburg effect in cancer cells. This
study aimed to evaluate metabolic alterations and biological behaviours after
knocking down PKM2. Methods In this study, 36 pairs of BCa tissues and adjacent
normal tissues were collected to analyse the expression level of PKM2 and to
explore the relationship between PKM2 level and tumour and patient status. After
PKM2 knockdown in T24 cells, cell survival, migration, invasion, glucose uptake,
lactate production, and apoptosis were detected. The tumour-forming ability of
PKM2-reducing T24 cells was examined in vivo . Results The results showed that
PKM2 expression correlates with BCa stage and grade. PKM2 knockdown decreases
glucose consumption and lactate production and suppresses cell proliferation,
migration, and invasion while increasing reactive oxygen species levels and
apoptosis in T24 BCa cells in vitro . In nude mouse models, PKM2 knockdown
reduced xenograft and orthotopic tumour size. Moreover, PKM2 knockdown decreased
vimentin and fibronectin expression and increased E-cadherin expression.
Analysis of high-throughput sequencing data revealed that PKM2 may also be
associated with biological processes and diseases. Conclusions Overall, these
results indicate that PKM2 may be a therapeutic target for BCa patients.

Es konnten keine Quellenangaben für dieses Dokument abgerufen werden

Quellenangabe für das Dokument wird abgerufen...
Open Access 3. Februar 2023

DEVELOPMENT AND VALIDATION OF A NOMOGRAM FOR PREDICTING SURVIVAL IN PATIENTS
WITH PANCREATIC DUCTAL ADENOCARCINOMA AFTER RADICAL PANCREATODUODENECTOMY

Yanwei Wang, Chenghao Cui, Qiang Yu, Mingtai Li, Yurong Liang
Seiten: 51-59
Mehr Zitieren PDF downloaden


ABSTRACT

Objectives Hypercoagulation and malnutrition are the characteristic
pathophysiological changes associated with pancreatic ductal adenocarcinoma
(PDAC), which are intimately related to cancer progression and prognosis. We
aimed to integrate related indicators to build a nomogram model to predict the
overall survival (OS) of PDAC patients underwent radical pancreatoduodenectomy
(PD). Methods Clinicopathological and survival data of 138 patients were
retrospectively analyzed according to inclusion and exclusion criteria. A
nomogram was built based on the multivariate Cox regression analysis. The
receiver operating characteristic curve (ROC) and calibration curves were
performed based on the bootstrap method to evaluate the predictive performance
of the nomogram. Decision curve analysis (DCA) was performed to assess the
clinical usefulness of the nomogram. Results High-grade tumor (Hazard ratio
[HR]: 3.70; 95% confidence interval [CI]: 1.51–3.82; p<0.001), vessel carcinoma
embolus (HR: 2.69; 95% CI: 1.30–5.31, p=0.007), N2 (HR: 2.90; 95% CI: 1.47–7.37;
p=0.004), anemia (HR: 1.98; 95% CI: 1.01–2.70; p=0.047), PLR>244.8 (HR: 2.13;
95% CI: 1.05–3.45; p=0.033), FBG>3.50 g/L (HR: 2.10; 95% CI: 1.04–3.09,
p=0.008), and DRR>1.1 (HR: 2.69; 95% CI: 1.56–4.27; p<0.001) served as
independent risk factors for poor OS of patients with PDAC underwent radical PD
and were implemented to construct a nomogram. The area under curve (AUCs) for
the first, second, and third years were 0.713, 0.777, and 0.845, respectively.
Besides, calibration curves fitted well to the ideal line. DCA shows that the
nomogram has greater net benefit than the existing TNM staging system,
suggesting that this model is a more practical clinical tool for predicting the
prognosis of PDAC patients. Conclusions The nomogram we established based on the
characteristic pathophysiological alterations of PDAC for predicting OS in
patients who underwent radical pancreatoduodenectomy presented considerable
predictive power. It may facilitate prognostic risk stratification and optimize
therapeutic decision-making.

Es konnten keine Quellenangaben für dieses Dokument abgerufen werden

Quellenangabe für das Dokument wird abgerufen...
Open Access 22. Februar 2023

SET DOMAIN CONTAINING PROTEIN 8 (SET8) PROMOTES TUMOUR PROGRESSION AND INDICATES
POOR PROGNOSIS IN PATIENTS WITH LARYNGEAL SQUAMOUS CELL CARCINOMA

Li-Li Lan, Sheng-Hui Liu, Zhi-Tao Fan, Xue-Xia Wang, Jing-Tian Wang, Ke-Xin
Wang, Rui-Li Zhao
Seiten: 61-69
Mehr Zitieren PDF downloaden


ABSTRACT

Objectives SET Domain Containing Protein 8 (SET8), a member of the SET domain
containing methyltransferase family involved in several biological processes and
SET8 expression levels, reportedly affects the outcomes of patients with breast
cancer, renal cancer, prostate carcinoma, and oesophageal squamous cell
carcinoma. However, there have been no relevant studies on the biofunction and
use of SET8 expression in the prediction of laryngeal squamous cell carcinoma
(LSCC) outcomes. Methods In our study, SET8 expression levels were detected
using immunohistochemical staining, western blotting, and quantitative real-time
RT-PCR (qRT-PCR) with semi-quantitative analysis for laryngeal cancer outcomes.
Additionally, we assessed the influence of SET8 on the behaviour of laryngeal
cancer cells in vitro , using cell counting kit-8, clone formation, wound
healing, and Transwell invasion assays. We subsequently performed qRT-PCR and
western blotting for an in-depth study of SET8. Results Our study showed marked
upregulation of SET8 in tumour tissues and laryngeal cancer cell lines. High
SET8 expression predicts poor prognosis in patients with LSCC, and its
expression can be used as an independent predictor of LSCC outcome. Subsequent
functional analyses indicated that SET8 knockdown exerted an inhibitory
effect on proliferation, migration, and invasiveness in vitro. Conclusions SET8
may be associated with epithelial-mesenchymal transition. Our results
demonstrate that higher SET8 expression is an unfavourable prognostic predictor
and exerts tumour-promoting effects in LSCC.

Es konnten keine Quellenangaben für dieses Dokument abgerufen werden

Quellenangabe für das Dokument wird abgerufen...
Open Access 8. Februar 2023

HYPOXIA-INDUCIBLE FACTOR 1Α (HIF-1Α)-ACTIVATED GLI1 INDUCES INVASION AND EMT BY
H3K4 METHYLATION IN GLIOMA CELLS

Yihai Lin, Zhangyi Wu
Seiten: 71-79
Mehr Zitieren PDF downloaden


ABSTRACT

Objectives Gliomas are highly aggressive neuroepithelial-layer malignancies.
Hypoxia-inducible factor 1α (HIF-1α) was revealed to be upregulated in gliomas
under hypoxia. Nevertheless, its role in glioma cells remains elusive. We
attempted to clarify the molecular mechanism of HIF-1 underlying glioma. Methods
Cellular models were established to mimic the characteristics of hypoxia.
RT‒qPCR was used to detect HIF-1α and Gli1 levels in glioma cells with or
without hypoxic treatment. Transwell assays were used to measure the invasive
ability of U87 and U251 cells. Western blotting was used to evaluate
epithelial-mesenchymal transition (EMT)-associated protein abundance and H3K4
methylation (H3K4me)-associated protein abundance in U87 and U251 cells. ChIP
assessed the association of HIF-1α or H3K4me with the Gli1 promoter in glioma
cells. Results HIF-1α and Gli1 were upregulated in glioma cells relative to
normal human astrocytes (NHAs). HIF-1α and Gli1 were also upregulated in
hypoxia-treated glioma cells relative to untreated glioma cells. Both HIF-1α and
Gli1 silencing suppressed glioma invasion and EMT under hypoxia. HIF-1α
upregulated Gli1 transcriptionally via MLL1-mediated H3K4me. H3K4me mutation
silencing was further demonstrated to suppress glioma cell invasion and EMT
under hypoxia. Conclusions Both HIF-1α and Gli1 are upregulated in glioma cells
and function as oncogenes in glioma cells. HIF-1α transcriptionally activates
Gli1 via MLL1-mediated H3K4 methylation in glioma cells, providing ideas for
seeking new therapeutic directions for glioma.

Es konnten keine Quellenangaben für dieses Dokument abgerufen werden

Quellenangabe für das Dokument wird abgerufen...
Open Access 10. Februar 2023

THE INHIBITORY EFFECTS OF LOBAPLATIN, OR IN COMBINATION WITH GEMCITABINE ON
TRIPLE-NEGATIVE BREAST CANCER CELLS IN VITRO AND IN VIVO

Chengyan Jiang, Ye Zhang, Xiaoyu Xu, Shanshan Su, Huafeng Pan, Aiqin Jiang
Seiten: 81-91
Mehr Zitieren PDF downloaden


ABSTRACT

Objectives To study the therapeutic effects of lobaplatin in combination with
conventional chemotherapy drugs on triple-negative breast cancer (TNBC) cells.
Methods We used the CCK-8 assay, flow cytometry, western blotting, and
immunofluorescence staining methods to detect the effects of lobaplatin or in
combination with gemcitabine on the survival, apoptosis, and cell cycle
progression of TNBC cells. A cell-derived xenograft mouse model was used to
verify the antitumor effects of lobaplatin alone or in combination with
gemcitabine. Results Lobaplatin significantly inhibited MDA-MB-468 cell growth
in vitro , either alone or in combination with gemcitabine. Lobaplatin arrested
the cell cycle at the S phase, induced nuclear cell damage, and promoted
apoptosis. Also, the percentage of apoptotic cells was greatly increased
when lobaplatin was combined with gemcitabine. Cleaved Caspase-3 and Poly
(ADP-Ribose) Polymerase-1 (PARP-1) fragments indicated that lobaplatin promoted
apoptosis through the classical pathway. Lobaplatin effectively inhibited the
growth of tumors in vivo . Compared with the vehicle group (567.6 ± 126.2 mm 3
), the tumor volume of the lobaplatin group (302.7 ± 131.6 mm 3 ) was
significantly reduced (p<0.01). The combination of lobaplatin and gemcitabine
(207.7 ± 83.94 mm 3 ) was a little better than lobaplatin alone in the
inhibition of the transplanted tumor (p>0.05). Conclusions Lobaplatin alone or
in combination with gemcitabine had significant inhibitory effects on MDA-MB-468
cells  in vitro . Lobaplatin also significantly inhibited the growth of nude
mice xenografts. The synergistic effect between lobaplatin and gemcitabine
in vivo was minimal, perhaps due to the low dose of gemcitabine used.



CASE REPORT

Es konnten keine Quellenangaben für dieses Dokument abgerufen werden

Quellenangabe für das Dokument wird abgerufen...
Open Access 7. Februar 2023

EPSTEIN–BARR VIRUS POSITIVE GASTRIC ADENOCARCINOMA WITH SYSTEMIC EBV
REACTIVATION IN A PATIENT WITH PERSISTENTLY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS

Rada Miskovic, Danijela Miljanovic, Maja Dimic Cumic, Ivana Lazarevic, Ana Banko
Seiten: 93-97
Mehr Zitieren PDF downloaden


ABSTRACT

Objectives Epstein–Barr virus (EBV) has been associated with several types of
cancers, most often with nasopharyngeal carcinomas and hematological
malignancies. It is also suggested that EBV has significant role in the
pathogenesis of different types of autoimmune diseases including systemic lupus
erythematosus (SEL). The exact mechanisms behind these processes are not
elucidated. Case presentation We present a case of a 52-years old female
patients with moderately active SLE presenting with severe fatigue, purpuric
lesions, alopecia, polyarthritis, mucosal ulcerations, and progressive
thrombocytopenia over a period of 10 months. During the work-up, the patient was
evaluated for several viral infections. Serology testing showed elevation of
anti-EBV, anti-CMV and anti-HSV1/2 IgM antibodies with the presence of IgG
antibodies against all mentioned viruses except HSV2. Corticosteroid therapy was
escalated, and azathioprine was introduced. Due to the persistence of
significant thrombocytopenia and monoclonal IgG sternal puncture was performed.
Morphological and immunohistochemical analysis of bone marrow specimen presented
infiltration with metastatic deposits of adenocarcinoma and monoclonal
plasmacytosis. Esophagogastroduodenoscopy showed multiple prepyloric erosions of
gastric mucosa, which were biopsied. Pathohistological analysis demonstrated
infiltration of gastric mucosa with diffuse type adenocarcinoma. Further PCR
testing of biopsied gastric adenocarcinoma revealed the presence of EBV DNA in
carcinoma tissue. The patient was sent to the oncologist for further evaluation.
Conclusions Assessment of SLE patients with persistently active disease should
include the analysis of the herpesvirus infection status. Reactivations of EBV
may be considered as possible trigger for lupus flares and the factor for
increased risk of developing malignancies.



AUSGABEN


AHEAD-OF-PRINT / JUST-ACCEPTED

 * Ahead-of-Print / Just-Accepted


BAND 25 (2023)

 * Heft 1


METRIKEN

Für diese Zeitschrift sind keine Journal Metrics verfügbar.


EINREICHEN


EINREICHEN

Submission
You can easily submit your manuscript online.
Simply go to http://mc.manuscriptcentral.com/oncologie and you will be guided
through the whole peer-reviewing and publishing process.

Your benefits of publishing with us

 * Open Access publication
 * Research freely available for all to read and download
 * Authors retain copyright – articles published under the Creative Commons
   Attribution (CC-BY-4.0) License
 * Rapid publication times
 * Free publication of color figures
 * Accepted papers will be published online first as DOI-citable, forward-linked
   articles for quickest possible visibility for the scientific community
 * Every article easily discoverable because of Search Engine Optimization (SEO)
   and comprehensive abstracting and indexing services
 * Professional sales and marketing activities

Submission process

 * Submission of your paper via our submission management tool following the
   Instructions for Authors
 * The article processing fees for publishing a research article is € 1.000
 * Single-blind peer review process
 * A decision on your paper is aspired within approx. 6 weeks
 * Accepted articles are published online approx. 4 weeks after acceptance

Please note



 * Before submitting your article please have a look at our Publication Ethics
   Statement and our License to Publish.
 * If you have any general questions please visit our FAQ page for journal
   authors.

We are looking forward to receiving your manuscript soon!


EDITORIAL


EDITORIAL

Editors-in-Chief

Jean-Philippe Metges
Institut de Cancérologie et d'Hématologie, CHRU de Brest, France
Digestive cancer; Targeted therapies and immunotherapy; Clinical management


Daniel Serin
Institut Sainte-Catherine, Avignon, France
Breast cancer; Fibrocystic breast disease; Clinical oncology


Associate Editors

Jean-Yves Blay
Centre Léon Bérard, Unicancer and Université Claude Bernard Lyon 1, Lyon, France
Sarcoma; Gastrointestinal stromal tumors; Breast cancer


Mario Campone
Institut de Cancérologie de l'Ouest, Site René Gauducheau, Site Hospitalier
Nord, Saint-Herblain, France
Breast cancer; Development of new drug; Translational research


Nadine Houédé
Institut de Cancérologie du Gard - CHU Caremeau; Institut de Recherche en
Cancérologie de Montpellier &Université de Montpellier, France
Prostate cancer; Bladder cancer; Renal cell carcinoma


Kun Huang
Tongji School of Pharmacy, Tongji Medical College, Huazhong University of
Science and Technology, Wuhan, China
Liver cancer; Renal carcinoma; Drug discovery


Nicolas Isambert
Centre Hospitalier Universitaire de Poitiers, France
Cancer biology; Cancer immunology; Tumor microenvironment


Tristan Montier
Université de Bretagne Occidentale (University of Western Brittany), Brest,
France
Cell and molecular biology; Gene delivery and gene therapy; Ovarian cancer


Haili Qian
State Key Laboratory of Molecular Oncology, National Cancer Center/National
Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical
Sciences and Peking Union Medical College, Beijing, China
Molecular oncology; Cancer biology; Immunotherapy; Tumor metastasis


Xavier Troussard
Laboratoire d'hématologie biologique, CHU de Caen Normandie, Caen, France
Leukemia; Multiple myeloma; Clinical trials


Hong Ping Xia
School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China
Hepatocellular carcinoma; Oncogene; Targeted therapeutic strategy


Editorial Board

Xavier Artignan
Department of Radiation Oncology, CHP St Grégoire, St Grégoire, France
Radiotherapy; Prostate cancer


Majid Asadi-Samani
Shahrekord University of Medical Sciences, Shahrekord, Iran
Biology; Medicinal plants; Pharmacognosy; Phytomedicine; Immunology; Cancer


Hossein Banazadeh Baghi
Immunology Research Center & Infectious and Tropical Diseases Research Center,
Department of Microbiology, Faculty of Medicine, Tabriz University of Medical
Sciences, Tabriz, Iran
Viruses and human cancer; Viral vaccines; Viral epidemiology


Giammauro Berardi
Department of General and Hepatobiliary Surgery, Liver Transplantation Service,
San Camillo Forlanini Hospital, Rome, Italy
Surgical oncology; Hepatobiliary and pancreatic surgery; Liver cancer; Liver
transplantation


Fulvio Borella
Obstetrics and Gynecology 1U, S. Anna Hospital, Turin, Italy
Gynecological cancer; Breast cancer; Prognostic/predictive factors; Cancer
biology


Giuseppe Broggi
Department of Medical, Surgical Sciences and Advanced Technologies "G.F.
Ingrassia", Anatomic Pathology, University of Catania, Catania, Italy
Histopathology; Surgical pathology; Dermatopathology


Hong Lei Chen
Department of Pathology, Medical School of Wuhan University, Wuhan, China
Tumor immunity and immunotherapy resistance mechanism; Autophagy, energy
metabolism and carcinogenesis; Pathological diagnosis of neoplasm


Delia Cannizzaro
Department of Neurosurgery, Humanitas Clinical and Research Center-IRCCS, Milan,
Italy and Department of Biomedical Sciences, Humanitas University, Milan, Italy
Neurosurgery

Francesco Cicone
Department of Experimental and Clinical Medicine, and Neuroscience Research
Centre, PET/RM Unit, "Magna Graecia" University of Catanzaro, Nuclear Medicine
Unit, University Hospital "Mater Domini", Catanzaro, Italy
PET/CT cancer diagnostics; Nuclear medicine therapy; Brain tumor imaging

Roberto Colasanti
Department of Neurosurgery, Padua University Hospital, Ancona, Italy
Neurosurgery; Neuro-oncology (Gliomas, Metastatic brain tumors, Pineal tumors,
etc.); Brain mapping; Skull base (Meningiomas, Schwannomas, etc.); Spine tumors

Jianxun Ding
Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied
Chemistry, Chinese Academy of Sciences, Changchun, China
Bioactive agents for tumor microenvironment regulation; Bioactive polymers for
controlled delivery of antineoplastic agents; Bioactive polymers as adjuvants
for cancer immunotherapy

Maya Dymova
Laboratory of Biotechnology, Institute of Chemical Biology and Fundamental
Medicine, Siberian Branch of the Russian Academy of Sciences (ICBFM SB RAS),
Novosibirsk, Russia
Mycobacterium tuberculosis; Molecular genetics; Molecular oncology

Yujiang Fang
Department of Microbiology & Immunology, Des Moines University, Des Moines, USA
Pathology of oncology; Cancer immunotherapy; Cancer radiosensitizer

Valéria Pereira Ferrer
Department of Cell and Molecular Biology, Fluminense Federal University, Rio de
Janeiro, Brazil
Prostate cancer and glioblastoma;Extracellular matrix; Angiogenese; New
therapies and biomarkers; Molecular biology; Cell biology; Biochemistry;
Oncology; Toxinology

Jean-Sébastien Frénel
Département d’Oncologie Médicale, Institut de Cancérologie de l’Ouest,
Saint-Herblain, France
Breast cancer; Gynecological cancer; Circulating biomarker

Nicola Fusco
Biobank for Translational and Digital Medicine Unit, IRCCS European Institute of
Oncology (IEO); Department of Oncology and Hemato-Oncology, University of Milan,
Milan, Italy
Breast pathology; Predictive pathology; Digital pathology; Translational
research

Zhaohui Gong
Biochemistry and Molecular Biology, Ningbo University School of Medicine,
Ningbo, China
Targeted therapy; Immunotherapy; Precision medicine

Frank Griesinger
Department of Haematology & Oncology, University Department Internal
Medicine-Oncology, Pius-Hospital, University Medicine Oldenburg, Germany
Thoracic Oncology; Non-Small Cell Lung Cancer

Gu He
Medicinal Chemistry, West China Hospital, Sichuan University, Chengdu, China
Cancer biology; Chemical biology; Computation chemistry

Xiaoyun He
Department of Ultrasound Imaging, Xiangya Hospital, Central South University,
Changsha, China
Molecular targeted therapy for metabolic diseases; Vascular endothelial tumors

Yi Hu
State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical
College Hospital, Chinese Academy of Medical Science, Beijing, China
Nanomedicines; Mitochondria; Macrophage

Guichun Huang
Medical Oncology Department of Jinling Hospital, Medical School of Nanjing
University, Nanjing, China
Tumor angiogenesis; Tumor microenvironment; Cancer immunotherapy

Haroon Khan
Department of Pharmacy, Faculty of Chemical & Life Sciences, Abdul Wali Khan
University, Mardan, Pakistan
Metabolic diseases; Pharmacology; Antioxidant activity

Ivana Lazarevic
Institute of Microbiology and Immunology, Faculty of Medicine, University of
Belgrade, Belgrade, Serbia
Viral genetic variability; Hepatitis viruses; Antiviral resistance

Anne Lesur
Institut de Cancérologie de Lorraine, Nancy, France
Clinical oncology; Breast cancer; Endocrine therapy

Xiangpan Li
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China
Clinical research: Follow-up; Materials collection and analysis; Research
design; Clinical epidemiology: Medical research method; Statistic analysis; Lab
skills: Animal model of lung cancer; cell culture; HE staining; PCR etc.

Yuchen Liu
Key Laboratory of Medical Reprogramming Technology, First Affiliated Hospital of
Shenzhen University, Shenzhen, China
Cancer Biology; DNA&RNA editing; Synthetic biology

François Lucia
Radiation Oncology Department, University Hospital of Brest, France
Gynecological Oncology

Xiaobin Lv
Cancer Center Lab, the Third Affiliated Hospital of Nanchang University,
Nanchang, China
Post-translational modification; Non-coding RNA; Chemotherapy resistance

Fabio Medas
General Surgery and Consultant at Department of General and Endocrine Surgery at
University Hospital of Cagliari, Cagliari, Italy
Cancer Surgery; Parathyroid carcinoma; Hernias

Jialin Meng
Department of Urology, the First Affiliated Hospital of Anhui Medical
University; Institute of Urology and Anhui Province Key Laboratory of
Genitourinary Diseases, Anhui Medical University, Hefei, Anhui, China
Cancer biology; Immunotherapy; Urologic disease; Biomarkers; Bioinformatics

Laurent Mineur
Institut Sainte-Catherine, Avignon, France
Gastric adenocarcinomas; Colorectal cancer; Liver tumors

Cem Önal
Department of Radiation Oncology, Faculty of Medicine, Adana Dr. Turgut Noyan
Research and Treatment Center, Baskent University, Adana, Turkey
Prostate cancer; Breast cancer; Gynecological malignancies;
Radiotherapy/radiosurgery; Helical tomotherapy

Armando Orlandi
Comprehensive Cancer Center, UOC di Oncologia Medica, Fondazione Policlinico
Universitario A. Gemelli IRCCS, Rome, Italy
Breast cancer

Chunlin Ou
Department of Pathology, Xiangya Hospital Central South University, Changsha,
China
Exosomal long non-coding RNAs; Oxidative stress; Colorectal cancer

Carlos Eduardo Paiva
Division of Breast & Gynecology, Department of Clinical Oncology, Barretos
Cancer Hospital, Barretos-SP, Brazil
Palliative and supportive care; Breast cancer; Quality of life

Stefano Rausei
University of Milan, Department of Surgery, ASST Valle Olona (Varese), Varese,
Italy
Surgical oncology; Gastric cancer; Colon cancer; Minimally invasive
surgery; Emergency surgery



Kandasamy Saravanakumar
Department of Medical Biotechnology, College of Biomedical Sciences, Kangwon
National University, Chuncheon, South Korea
Cellular antioxidant properties; Antibacterial activity; Paraconiothyrium
brasiliense


Gianluca Scalia
Department of Head and Neck Surgery, Neurosurgery Unit, Garibaldi Hospital,
Catania, Italy
Gliomas; Meningiomas; Spine tumors

Mohsen Sheykhhasan
Research Center for Molecular Medicine, Hamadan University of Medical Sciences,
Hamadan, Iran
Stem Cell; CAR T cell therapy; Exosomes


Hardeep Singh Tuli
Department of Biotechnology, Maharishi Markandeshwar University, Haryana, India
Cancer biology; Cell signaling; Gene expression


Johnson Stanslas
Pharmacotherapeutics Unit, Department of Medicine, Faculty of Medicine and
Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia
Clinical and experimental pharmacology; Drug discovery; Translational
therapeutics; Cancer research and neuroscience


Farzad Taghizadeh-Hesary
Department of Radiation Oncology, Iran University of Medical Sciences, Tehran,
Iran
Radiation oncology; Clinical radiotherapy; Radiation biology; Combined modality
therapy; Medical oncology; Chemotherapy; Targeted therapies; Cancer biology

Dilek Telci
Department of Genetics and Bioengineering, Yeditepe University, Istanbul, Turkey
Cell signaling in cancer; Cell adhesion; Migration and metastasis; Animal models
in cancer


Giuseppe E. Umana
Department of Neurosurgery, Cannizzaro Hospital, Trauma Center, Gamma Knife
Center, Catania, Italy
Neuro-oncology; Stereotactic radiosurgery; Skull base; gliomas; Meningiomas;
Schwannomas; Craniovertebral junctions tumors; Spine tumors; Peripheral nerve
sheath tumors


Dimitrios-Efthymios Vlachos
First Department of Obstetrics and Gynecology University of Athens, Greece
Gynecological Oncology

Feng Wang
Department of Clinical Laboratory Center, Affiliated Hospital of Nantong
University, Nantong, China
Tumor pathogenesis; Cancer molecular diagnosis; Non-coding RNA


Dongkui Xu
Department of VIP, National Cancer Center/National Clinical Research Center for
Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union
Medical College, Beijing, China
Colorectal cancer; Gastric cancer; Surgery, including minimally invasive surgery

Kexin Xu
Department of Molecular Medicine, University of Texas Health Science Center at
San Antonio, San Antonio, USA
Epigenomics; Functional genomics; Genome editing


Tao Xu
School of Pharmacy, Anhui Medical University, Hefei, China
The mechanism of liver inflammation; Pathogenesis of alcoholic liver disease;
Hospital humanities


Shun Fa Yang
Institute of Medicine, Chung Shan Medical University, Taiwan, China
Biomarkers; Environmental toxicology; Cell signaling


Paul Zarogoulidis
Pulmonary Department, "General Clinic Euromedica" Private Hospital,
Thessaloniki, Greece
Lung cancer diagnosis and treatment; Drug design development and therapy


Yingchun Zeng
School of Medicine, Zhejiang University City College, Hangzhou, China
Clinical psychology; Nursing science; Rehabilitation medicine


Wenwen Zhang
Department of Oncology, Nanjing First Hospital, Nanjing Medical University,
Nanjing, China
Breast cancer; Metastasis; Biomarkers

(English)
 * Typ: Zeitschrift
 * Sprachen: Englisch, Französisch
 * Verlag: De Gruyter
 * Erstveröffentlichung: 1. Januar 2023
 * Erscheinungsweise: 6 Hefte pro Jahr


Fachgebiete
 * Allgemein
 * Altertumswissenschaften
 * Architektur und Design
 * Asien- und Pazifikwissenschaften
 * Bibliotheks- und Informationswissenschaft, Buchwissenschaft
 * Biologie
 * Chemie
 * Geowissenschaften
 * Geschichte
 * Industrielle Chemie

 * Informatik
 * Islam- und Nahostwissenschaft
 * Jüdische Studien
 * Kulturwissenschaften
 * Kunst
 * Linguistik und Semiotik
 * Literaturwissenschaft
 * Materialwissenschaft
 * Mathematik
 * Medizin

 * Musik
 * Pharmazie
 * Philosophie
 * Physik
 * Rechtswissenschaften
 * Sozialwissenschaften
 * Sport und Freizeit
 * Technik
 * Theologie und Religion
 * Wirtschaftswissenschaften

Services
 * Für Zeitschriftenautoren
 * Für Buch-Autoren
 * Für Bibliothekare
 * Rechte & Berechtigungen

Publikationen
 * Publikationsarten
 * Open Access

Über uns
 * Kontakt
 * Karriere
 * Über De Gruyter
 * Partnerverlage
 * Presse
 * FAQs

Social
 * Facebook
 * Instagram
 * LinkedIn
 * Twitter
 * YouTube

Gewinner des OpenAthens
Best Publisher UX Award 2022
 * Facebook
 * Instagram
 * LinkedIn
 * Twitter
 * YouTube

Gewinner des OpenAthens
Best Publisher UX Award 2022

 * Hilfe/FAQ
 * Datenschutzerklärung
 * Cookie Richtlinien
 * Barrierefreiheit
 * AGB
 * Impressum

© Walter de Gruyter GmbH 2023

Heruntergeladen am 17.3.2023 von
https://www.degruyter.com/journal/key/oncologie/html


Wir verwenden Cookies, um Ihr Nutzungserlebnis zu verbessern.
Hier erfahren Sie, wie wir Cookies verwenden.
Alle Cookies akzeptierenNicht notwendige Cookies ablehnen
Ihre Auswahl wurde gespeichert. Um Ihre Einstellungen zu ändern, gehen Sie zu
unseren Cookie-Richtlinien.
Schließen